Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study

Ann Oncol. 1992 Nov;3(9):768-70. doi: 10.1093/oxfordjournals.annonc.a058337.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / secondary*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage*
  • Female
  • Fluorouracil / administration & dosage
  • Fluoxymesterone / administration & dosage
  • Humans
  • Methotrexate / administration & dosage
  • Mitolactol / administration & dosage
  • Neoplasm Recurrence, Local
  • Prednisone / administration & dosage
  • Prospective Studies
  • Remission Induction
  • Survival Rate
  • Tamoxifen / administration & dosage

Substances

  • Tamoxifen
  • Doxorubicin
  • Cyclophosphamide
  • Fluoxymesterone
  • Mitolactol
  • Fluorouracil
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CDPTH regimen
  • CMFPTH regimen